NCT03891953 2026-01-21Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.NovartisPhase 1 Active not recruiting98 enrolled
NCT02936102 2025-11-14A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated154 enrolled
NCT01351103 2025-06-13A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsNovartisPhase 1 Completed185 enrolled
NCT03294694 2025-05-31Ribociclib + PDR001 in Breast Cancer and Ovarian CancerDana-Farber Cancer InstitutePhase 1 Terminated33 enrolled
NCT03549000 2024-12-13A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated127 enrolled
NCT02890069 2023-01-11A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNovartisPhase 1 Completed298 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT02947165 2022-01-31Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.NovartisPhase 1 Completed120 enrolled